Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma |
| |
| Authors: | Claude Jacquillat David Khayat Pierre Banzet Maryse Weil Marie-Francoise Avril Pierre Fumoleau Moïse Namer Jean Bonneterre Pierre Kerbrat Jean-Jacques Bonerandi Roland Bugat Philippe Montcuquet Bruno Audhuy Didier Cupissol Richard Lauvin Edouard Grosshans Catherine Vilmer Chantal Prache Jean-Pierre Bizzari |
| |
| Affiliation: | (1) Oncology department of Hôpital Pitié-Salpêtrière, Paris, France;(2) Oncology department of Hôpital St. Louis, Paris, France;(3) Oncology department of Institut G. Roussy, Villejuif, France;(4) Oncology department of Centre R. Gauducheau, Nantes, France;(5) Oncology department of Centre A. Lacassagne, Nice, France;(6) Oncology department of Centre O. Lambret, Lille, France;(7) Oncology department of Centre E. Marquis, Rennes, France;(8) Oncology department of Hôpital Ste Marguerite, Marseille, France;(9) Oncology department of Centre C. Regaud, Toulouse, France;(10) Oncology department of CHU de Besançon, Besancon, France;(11) Oncology department of CHU Pasteur, Colmar, France;(12) Oncology department of Centre Val d'Aurelle, Montpellier, France;(13) Oncology department of Hôpital Sud, Rennes, France;(14) Oncology department of Hôpital Civil, Strasbourg, France;(15) Oncology department of Centre R. Huguenin, St. Cloud, France;(16) Service d'Oncologie, Médicale, Pavillon Jacquart, Hôpital Pitié Salpétrière, 47 bd de l'Hôpital, F-75651 Paris Cedex 13, France |
| |
| Abstract: | Summary A total of 42 patients with cerebral metastases of malignant melanoma were included in this study of the nitrosourea fotemustine. The treatment plan consisted of a 1-h i. v. infusion of 100 mg/m2 fotemustine every week for 3–4 weeks, followed by a 4- to 5-week rest period. Responding or stabilised patients then received 100 mg/m2 fotemustine every 3 weeks. Among the 39 evaluable patients, 2 complete responses and 9 partial responses were documented, leading to an overall response rate of 28.2%. Most of the responses were obtained in previously untreated patients and/or those presenting with a single cerebral metastasis. Toxicity was mild and mainly hematological, especially in patients previously treated by polychemotherapeutic regimen. Our study confirms the activity of fotemustine in cerebral metastases of disseminated malignant melanoma.Others institutions involved in this trial: A. Bernadou, Hôtel Dieu, Paris; J. Clavier, CHR de Brest; M. Delaunay, Hôpital Pellegrin Tripode, Bordeaux; J. P. Escande, Hôpital Tarnier, Paris; P. Fargeot, Centre George François Leclerc, Dijon; P. Lauret, Hôpital Charles Nicolle, Rouen; R. Leblay, Hôpital Sud, Rennes; P. Litoux, CHR de Nantes; G. Lorette, Hôpital Trousseau, Tours; R. Metz, Centre Alexis Vautrin, Nancy; A. Monnier, CHR Boulloche, Montbelliard; M. Mousseau, CHR de la Tronche, Grenoble; J. P. Olivier, Hôpital Dupuytren, Limoges; R. Touraine, Hôpital Henri Mondor, Créteil; F. Truchetet, Hôpital de Thionville, France |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
